Gracell Biotechnologies Inc. (GRCL): Price and Financial Metrics
GET POWR RATINGS... FREE!
GRCL Stock Price Chart Interactive Chart >
GRCL Price/Volume Stats
| Current price | $5.14 | 52-week high | $15.00 |
| Prev. close | $4.99 | 52-week low | $1.68 |
| Day low | $4.91 | Volume | 54,500 |
| Day high | $5.41 | Avg. volume | 232,545 |
| 50-day MA | $3.13 | Dividend yield | N/A |
| 200-day MA | $6.03 | Market Cap | 347.49M |
Gracell Biotechnologies Inc. (GRCL) Company Bio
Gracell Biotechnologies Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing cell therapies to address medical needs in the treatment of cancer. Gracell Biotechnologies aims to disrupt conventional approaches to CAR-T cell therapies with technology platforms-FasTCAR and TruUCAR.
Latest GRCL News From Around the Web
Below are the latest news stories about Gracell Biotechnologies Inc that investors may wish to consider to help them evaluate GRCL as an investment opportunity.
Gracell Biotechnologies Announces Multiple Advancements of TruUCAR Allogeneic CAR-T PlatformGracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced multiple advancements of its TruUCAR platform, the Company's proprietary technology platform designed to generate high-quality allogeneic CAR-T cell therapies that can be administered "off-the-shelf" as stand-alone therapy at lower cost and with greater conve |
Week In Review: China's NMPA Approves Pfizer's Oral COVID-19 Therapy PaxlovidDeals and Financings Shanghai AffaMed recently in-licensed ex-Asia (plus Japan) rights to a novel bispecific biologic molecule aimed at retinal vascular diseases from AskGene Pharma of Southern California. Today, AffaMed announced US approval to start clinical trials of the candidate, AM712, a dual inhibitor of vascular endothelial growth factor (VEGF)... |
Gracell Biotechnologies Doses First Patients in First-in-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's LymphomaGracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it has dosed multiple patients in a clinical trial evaluating GC012F, the Company's autologous CAR-T therapeutic candidate dual-targeting B cell maturation antigen (BCMA) and CD19 in B-cell non-Hodgkin's lymphoma (B-NHL). NHL is the fifth most common can |
Gracell Biotechnologies to Participate in Citi 2022 Virtual Immuno-Oncology SummitSUZHOU, China and PALO ALTO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the Citi 2022 Immuno-Oncology Summit on February 16th. Dr. William Cao, Founder, Chairman and CEO of Gracell will participate in a fireside cha |
Gracell Biotechnologies to Participate in B Riley Securities 2022 Virtual Oncology ConferenceSUZHOU, China and PALO ALTO, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the B Riley Securities 2022 Virtual Oncology Conference from January 27th to 28th. The Gracell team is scheduled to have a presentation at 2:30 |
GRCL Price Returns
| 1-mo | 63.17% |
| 3-mo | 111.52% |
| 6-mo | -9.03% |
| 1-year | -61.98% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -14.90% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...